Evaluating the Efficacy of Neoadjuvant Endocrine Therapy in HER2-Low Versus HER2-Negative Breast Cancer
Clinical Breast Cancer · 2026
DOI: 10.1016/j.clbc.2026.07.003 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Clinical Breast Cancer, 2026. Verfasst von Esther G Chong und 4 weiteren Autor:innen. Beteiligte Einrichtung: Department of Hematology and Oncology, Oregon Health and Science University, Portland, OR. Electronic address: chonge@ohsu.edu. Hauptthemen laut MEDLINE: Neoadjuvant Therapy, Breast Neoplasms, Erb-b2 Receptor Tyrosine Kinases, Antineoplastic Agents, Hormonal. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 19 Literaturangaben.
Abstract (Originalsprache)
HER2-low breast cancer has emerged as a distinct biological subtype with implications for treatment response. However, its impact on response to neoadjuvant endocrine therapy (NET) in hormone receptor-positive (HR+) breast cancer remains unclear. The objective of this study is to evaluate whether HER2-low status is associated with improved clinical response to NET among patients with early-stage HR+ breast cancer. A retrospective cohort study was conducted using data from the NCDB from 2010 to 2017, identifying women aged ≥ 18 years with stage I-III HR+ invasive breast cancer treated with NET, who had known HER2 immunohistochemistry status and response to NET documented. The primary outcome was clinical response to NET. We employed multivariable binomial logistic regression to examine how clinicopathologic factors influence the probability of any response to neoadjuvant hormonal therapy. Among the 3808 women included, 1055 patients had HER2-negative disease, and 2753 patients were HER2-low. Among HER2-low patients, 37 had pathological complete response (CR), and 1097 had pathologic response (PR). Among HER2-negative patients, 11 had pathological CR, and 387 had PR. Multivariable logistic models revealed that age, duration of NET, and HER2 status were significant predictors of any response to NET. HER2-low tumors were more likely to have any response compared to HER2-negative. HER2-low status had improved response to NET among women with early-stage HR+ breast cancer, which supports the concept of HER2-low disease as a distinct therapeutic entity and may inform individualized treatment strategies for endocrine-based therapies.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Hematology and Oncology, Oregon Health and Science University, Portland, OR. Electronic address: chonge@ohsu.edu.
- Department of Hematology and Oncology, Loma Linda University, Loma Linda, CA.
- Department of Internal Medicine, Loma Linda University, Loma Linda, CA.
- Department of Hematology and Oncology, City of Hope, Duarte, CA.
- Department of Radiation Oncology, Ichan School of Medicine at Mount Sinai, New York City, NY.
Zitieren
APA
Chong, E. G., Guo, M., Bera, K., Castillo, D., & Wu, P. (2026). Evaluating the Efficacy of Neoadjuvant Endocrine Therapy in HER2-Low Versus HER2-Negative Breast Cancer. Clinical Breast Cancer. https://doi.org/10.1016/j.clbc.2026.07.003
Vancouver
Chong EG, Guo M, Bera K, Castillo D, Wu P. Evaluating the Efficacy of Neoadjuvant Endocrine Therapy in HER2-Low Versus HER2-Negative Breast Cancer. Clinical Breast Cancer. 2026. doi:10.1016/j.clbc.2026.07.003
BibTeX
@article{Chong2026,
author = {Chong, Esther G and Guo, Mengni and Bera, Kevin and Castillo, Dani and Wu, Peter},
title = {Evaluating the Efficacy of Neoadjuvant Endocrine Therapy in HER2-Low Versus HER2-Negative Breast Cancer},
journal = {Clinical Breast Cancer},
year = {2026},
doi = {10.1016/j.clbc.2026.07.003}
}
EUVIMED